- HCV NS5A replication complex inhibitors. Part 3
-
In a recent disclosure,1 we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting 50 in a genotype 1b replicon assay.
- Lopez, Omar D.,Nguyen, Van N.,St. Laurent, Denis R.,Belema, Makonen,Serrano-Wu, Michael H.,Goodrich, Jason T.,Yang, Fukang,Qiu, Yuping,Ripka, Amy S.,Nower, Peter T.,Valera, Lourdes,Liu, Mengping,O'Boyle II, Donald R.,Sun, Jin-Hua,Fridell, Robert A.,Lemm, Julie A.,Gao, Min,Good, Andrew C.,Meanwell, Nicholas A.,Snyder, Lawrence B.
-
p. 779 - 784
(2013/02/25)
-
- HEPATITIS C VIRUS INHIBITORS
-
The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein
- -
-
Page/Page column 266
(2011/07/30)
-